Primary contact

AiCure's intelligent medical assistant, IMA, combines the advances in Artificial Intelligence through deep learning, computer vision, machine learning and predictive analytics to monitor patient progress. Mobile-enabled, IMA provides visual dose confirmation (medication ingestion), interactive patient support and engagement, and visual diagnostic capabilities. With almost 100 patents awarded or pending and funding from leading institutional investors and the National Institutes of Health, the platform has been validated to improve patient behavior in randomized controlled trials. HIPAA-compliant, AiCure is revolutionizing drug development and clinical care by ensuring that high quality treatments reach the patients that need them most. Usage areas Clinical research AiCure is being deployed across multiple therapeutic areas to measure and optimize medication adherence, and improve health outcomes. It supports automated tasks such as titration, reminders, and scheduling; provides adherence trends; and can log participant events with the ability to intervene in real time. Population health With AiCure, physicians can leverage the one-to-many platform, improve patient behavior, benefit from actionable data, and extend continuity of care. AiCure can be deployed on any smartphone, allowing physicians to define escalation and intervention protocols as well as side effect reporting. Available under a SaaS model, it becomes more economical as volume increases.
Primary contact

Funding 💰

Total $27.3M
Select investors New Leaf Venture Partners, Tribeca Venture Partners, Pritzker Group, Biomatics Capital, Baird Capital
Last update: April 23, 2018